The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG‐PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG‐PET (16%), and amyloid‐PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy‐nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“Alternatively, because MTA becomes abnormal late in the disease process [18], it may lack”
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“The International Working Group [1,2] and National Institute on Aging–Alzheimer’s Association criteria [3–5] recognize the importance of imaging and cerebrospinal fluid (CSF) markers for the early diagnosis of Alzheimer’s disease (AD) at the stage of mild cognitive impairment (MCI).”
BackgroundSelf-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“The pattern of low Ab42 and high total tau and phospho-tau has been referred to as the “AD signature” [25–27].”
BackgroundKnopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · cited 4×
“Use of biomarkers and reading tools volumetry Only traditional read 12/33 36 FDG-PET Not included 9/29 31 included 20/29 69 Statistical maps [48,49] 4/20 20 Scalar metrics [39,40] 2/20 10 Only traditional read 14/20 70 Amyloid-PET Not included 9/14 64 included 5/14 36 Statistical maps [49] 1/5 20 Structured visual ass…”
BackgroundInfluentialDiscrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832 · cited 2×
“Use of biomarkers and reading tools volumetry Only traditional read 12/33 36 FDG-PET Not included 9/29 31 included 20/29 69 Statistical maps [48,49] 4/20 20 Scalar metrics [39,40] 2/20 10 Only traditional read 14/20 70 Amyloid-PET Not included 9/14 64 included 5/14 36 Statistical maps [49] 1/5 20 Structured visual ass…”
BackgroundSelf-citationPatterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease
Chan, D., Fox, N. C., Scahill, R. I., Crum, W. R., Whitwell, J. L., Leschziner, G., Rossor, A. M., Stevens, J. M., Cipolotti, L., & Rossor, M. N. (2001) · Annals of Neurology · doi:10.1002/ana.92 · Cited by 749 · cited 1×
“Last, hippocampal atrophy is known to lack specificity, as it can be present in non-AD forms of dementia, like vascular dementia [19,20], semantic dementia [21], Parkinson’s dementia [20], and frontotemporal lobar degeneration [22].”
BackgroundEFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184 · cited 2×
“Some structured programs are currently ongoing where MCI patients are assessed by traditional clinical assessment supportedbyanextended rangeof core biomarkers that include MTA, CSFAb/tau, and hypometabolismon FDG-PET [7–10].”
BackgroundSelf-citationBastos-Leite, A. J., van der Flier, W. M., van Straaten, E. C. W., Staekenborg, S. S., Scheltens, P., & Barkhof, F. (2007) · Stroke · doi:10.1161/strokeaha.107.490102 · Cited by 128 · cited 1×
“Last, hippocampal atrophy is known to lack specificity, as it can be present in non-AD forms of dementia, like vascular dementia [19,20], semantic dementia [21], Parkinson’s dementia [20], and frontotemporal lobar degeneration [22].”
Background
Cited by
Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference
Morley, J. E., Morris, J. C., Berg-Weger, M., Borson, S., Carpenter, B. D., del Campo, N., Dubois, B., Fargo, K., Fitten, L. J., Flaherty, J. H., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.06.017 · Cited by 328
Self-citationManagement of mild cognitive impairment (MCI): The need for national and international guidelines
Kasper, S., Bancher, C., Eckert, A., Förstl, H., Frölich, L., Hort, J., Korczyn, A. D., Kressig, R. W., Levin, O., & Palomo, M. S. M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1696473 · Cited by 233
“In addition to a clinical diagnosis of MCI, the modified criteria proposed by the IWG and the NIA-AA include the presence of biomarkers indicative for AD pathophysiology; these criteria are commonly used in clinical practice in Europe for diagnosis and communication to MCI patients (Bocchetta et al. 2015; Bertens et a…”
MethodSelf-citation“New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)
Nelson, P. T., Trojanowski, J. Q., Abner, E. L., Al-Janabi, O. M., Jicha, G. A., Schmitt, F. A., Smith, C. D., Fardo, D. W., Wang, W.-X., Kryscio, R. J., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw033 · Cited by 158
“A first-line biomarker used for diagnosing the cause of cognitive impairment in the elderly is brain MRI (38).”
BackgroundInfluentialHerukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141
Self-citationUnbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Bertens, D., Tijms, B. M., Scheltens, P., Teunissen, C. E., & Visser, P. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0233-7 · Cited by 91
“likely to impact communication with and management of patients [30].”
BackgroundSelf-citation
Metadata
- Authors
- Bocchetta, M., Galluzzi, S., Kehoe, P. G., Aguera, E., Bernabei, R., Bullock, R., Ceccaldi, M., Dartigues, J., de Mendonça, A., Didic, M., Eriksdotter, M., Félician, O., Frölich, L., Gertz, H., Hallikainen, M., Hasselbalch, S. G., Hausner, L., Heuser, I., Jessen, F., Jones, R. W., Kurz, A., Lawlor, B., Lleo, A., Martinez‐Lage, P., Mecocci, P., Mehrabian, S., Monsch, A., Nobili, F., Nordberg, A., Rikkert, M. O., Orgogozo, J., Pasquier, F., Peters, O., Salmon, E., Sánchez‐Castellano, C., Santana, I., Sarazin, M., Traykov, L., Tsolaki, M., Visser, P. J., Wallin, Å. K., Wilcock, G., Wilkinson, D., Wolf, H., Yener, G., Zekry, D., & Frisoni, G. B.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-08-21
- Volume
- 11
- Issue
- 2
- Pages
- 195
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2034953421
- Cited by
- 76
- References
- 14
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.